Unique ID issued by UMIN | UMIN000024338 |
---|---|
Receipt number | R000028004 |
Scientific Title | Study of Lactic Acid Bacteria for Inhibition of Blood Sugar Elevation after Sucrose Intake in Human |
Date of disclosure of the study information | 2016/10/08 |
Last modified on | 2017/01/05 14:39:20 |
Study of Lactic Acid Bacteria for Inhibition of Blood Sugar Elevation after Sucrose Intake in Human
Study of Lactic Acid Bacteria for Inhibition of Blood Sugar Elevation after Sucrose Intake in Human
Study of Lactic Acid Bacteria for Inhibition of Blood Sugar Elevation after Sucrose Intake in Human
Study of Lactic Acid Bacteria for Inhibition of Blood Sugar Elevation after Sucrose Intake in Human
Japan |
Healthy adults
Borderline diabetes
Type 2 diabetes
Endocrinology and Metabolism | Adult |
Others
NO
Verify suppressive effect of postprandial glucose level elevation by lactic acid bacteria (viable and killed bacteria)
Efficacy
Blood glucose level after the sucrose tolerance test
Area under the curve for blood glucose level
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
2
Prevention
Other |
Conduct sucrose tolerance test for both cases of intake and non-intake of lactic acid bacterium solution by 50ml (killed and viable bacteria) by taking an interval of about a week.
Lactic acid bacterium intake ten minutes later
Conduct sucrose tolerance test for both cases of intake and non-intake of lactic acid bacterium solution by 50ml (killed and viable bacteria) by taking an interval of about a week.
Lactic acid bacterium intake one day later
20 | years-old | <= |
60 | years-old | >= |
Male
1) Japanese healthy (including borderline
diabetes) male
2) Fasting blood sugar: Lower than 125 mg/dL
3) Subjects who is not a diabetes
1) HbA1c are more than 7.0%
2) Subjects using medical products
3) Subjects who could start having allergic symptom in relation to test products
4) Subjects who use health food and supplements affecting blood glucose
5) Heavy drinker of alcohol
6) Subjects who participated in other clinical trials within the last four weeks prior to the current clinical trial
7) Subjects who have participated in a testregarding to the said lactic acid bacteriain the past.
8) Subjects judged inappropriate for the study by the investigator.
30
1st name | |
Middle name | |
Last name | Setsuo Hasegawa |
Pharmaspur Inc.
-
Toyo Building, 1-2-10 Nihonbashi, Chuo-ku, Tokyo
03-6214-2670
setsuo_hasegawa@pharmaspur.com
1st name | |
Middle name | |
Last name | Michiko Kainuma |
Pharmaspur Inc.
-
Toyo Building, 1-2-10 Nihonbashi, Chuo-ku, Tokyo
03-6214-2670
michiko_kainuma@pharmaspur.com
Pharmaspur Inc.
Genome Pharmaceuticals Institute Co., Ltd.
Other
NO
医療法人社団 冠心会 大崎病院 東京ハートセンター 臨床薬理研究所
2016 | Year | 10 | Month | 08 | Day |
Unpublished
Completed
2016 | Year | 09 | Month | 21 | Day |
2016 | Year | 11 | Month | 11 | Day |
2016 | Year | 10 | Month | 07 | Day |
2017 | Year | 01 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028004
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |